AstraZeneca is one step closer to acquiring Alexion Pharmaceuticals having been cleared by the US Federal Trade Commission after an antitrust review, the company stated.
The Cambridge, UK, pharmaceutical and biotechnology company said the US clearance follows competition clearances in Canada, Brazil, Russia, and other countries globally.
“Additional global regulatory clearances are pending, including but not limited to the UK, EU and Japan,” the company added.
The deal is valued at US$39 billion. AstraZeneca expects to close the acquisition in the third quarter.
AstraZeneca in December agreed to pay US$175 a share for the Boston pharmaceutical company, which is known for its focus on rare and ultra-rare disease. Alexion holders will own around 15% of AstraZeneca’s shares outstanding when the deal closes.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
FTC Urged to Enforce Rarely Used Antitrust Law Against Retail Giants
Mar 28, 2024 by
CPI
UK’s Fingleton Bolsters Team with New Additions
Mar 28, 2024 by
CPI
Britain’s Competition Regulator Clears Aviva’s Acquisition of AIG Life UK
Mar 28, 2024 by
CPI
White House Implements New AI Safeguards to Protect Rights and Safety
Mar 28, 2024 by
CPI
Denver Court Sets August Date for Kroger-Albertsons Merger Showdown
Mar 28, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Real Estate & Antitrust
Mar 27, 2024 by
CPI
Systematic National Evidence of Steering by Real Estate Agents
Mar 27, 2024 by
CPI
Compliance Now! Actionable Antitrust Advice for the Residential Real Estate Industry
Mar 27, 2024 by
CPI
Real Estate Commissions: Some Insights from the Economics of Multi-Sided Platforms
Mar 27, 2024 by
CPI
New Ideas for Promoting Real Estate Brokerage Price Competition
Mar 27, 2024 by
CPI